Highest-materiality recent filing
AYTU terminates Metadate CD license agreement with Lannett
Mutual termination effective June 23, 2026; certain provisions survive per Termination Agreement.
Aytu BioPharma Q3 net loss $5.6M; EXXUA launch revenue $2.4M
Net revenue $12.4M, down 33% YoY from $18.5M; net loss $5.6M vs net income $4.0M.
Aytu BioPharma amends warrants to enable equity classification; expects liability reduction
Amended warrants from 2023 and 2025 offerings to clarify stockholder vote cannot change beneficial ownership blockers.
Aytu BioPharma Q2 fiscal 2026 net loss $10.6M; EXXUA launch generates $0.2M initial revenue
Net revenue $15.2M, down 6% YoY; net loss $10.6M vs net income $0.8M, includes $8.2M derivative warrant liability loss.
Aytu BioPharma launches EXXUA for MDD; reports $32.6M cash, reduced launch budget to $6-8M
EXXUA (gepirone) is first FDA-approved 5HT1a agonist for MDD; full commercial launch underway after Dec 15, 2025 initial availability.
Aytu BioPharma stockholders elect all director nominees, ratify auditor, approve say-on-pay
All five incumbent directors reelected: Disbrow, Donofrio, Dockery, Jain, Liu with majority votes.
Aytu BioPharma reports Q1 FY2026 revenue $13.9M, net income $2.0M; EXXUA launch on track
Net revenue $13.9M vs $16.6M year ago; ex-one-time rebate of $3.3M, revenue up 5% YoY.
Aytu BioPharma reports FY2025 net revenue $66.4M, net loss $13.6M; plans EXXUA launch in Q4 2025
Full year net revenue $66.4M (+2% YoY); net loss $13.6M vs $15.8M prior year; adjusted EBITDA $9.2M.
Aytu BioPharma terminates AR101 asset purchase agreement; rights transferred to EnzCo
Company transferred all rights, title and interest in AR101 to EnzCo on August 5, 2025.
Term loan principal increased to $13.0M from $11.1M; maturity extended to June 12, 2029.
Aytu BioPharma posts updated investor presentation highlighting EXXUA opportunity
Presentation posted on June 17, 2025 for use in upcoming investor meetings.
Aytu BioPharma closes $16.6M upsized public offering; EXXUA launch planned Q4 2025
Gross proceeds $16.6M from 1.37M shares at $1.50 and pre-funded warrants; overallotment fully exercised for 1.44M additional shares.
Aytu BioPharma secures exclusive U.S. commercialization rights to EXXUA (gepirone) for MDD
Upfront cash payment of $3M; second payment of $3M due 1-year post-launch, increasing to $5M if first-year net sales exceed $35M.
Aytu BioPharma prices $14.4M upsized public offering of common stock and prefunded warrants
Priced upsized public offering of 9,600,000 shares of common stock (or prefunded warrants) at $1.50 per share.
Aytu BioPharma shareholders approve 300,000-share increase to equity plan; all directors reelected
Shareholders approved Plan Amendment raising shares reserved under 2023 Equity Plan from 200,000 to 500,000 (increase of 300,000).
Aytu BioPharma Q3 FY2025 net income $4M, revenue up 32% YoY to $18.5M
Net income of $4.0M ($0.65 basic / $0.21 diluted EPS) vs net loss of $2.9M a year ago.
Aytu BioPharma reports Q2 net income $0.8M; Pediatric revenue up 86% sequentially
Net revenue $16.2M, down 13% YoY; ADHD revenue fell 17% to $13.8M, Pediatric rose 12% to $2.4M.
Aytu settles derivative shareholder suit; court hearing Jan 13, 2025
Settlement approval hearing scheduled for January 13, 2025 in Delaware Chancery Court.
Aytu BioPharma Q1 net income $1.5M; promotes Ryan Selhorn as CFO
Net income of $1.5M vs net loss of $8.1M YoY; diluted EPS $0.15 loss vs $1.48 loss.
Exclusive collaboration, distribution and supply agreement with Lupin Pharma Canada for Aytu's ADHD products.
Aytu BioPharma FY2024 revenue $81M, adjusted EBITDA $9.2M; ADHD net revenue +23%
FY2024 consolidated net revenue $81.0M (down 25% YoY); net loss $15.8M ($2.86/share)
Divested Consumer Health (Innovus Pharmaceuticals) to an undisclosed private e-commerce company after winding down operations.
Aytu BioPharma annual meeting elects all directors, ratifies auditor, approves say-on-pay
All five incumbent directors elected with majority votes; Joshua Disbrow received 2,111,846 for, 596,291 withheld.
Aytu refinances $15M term loan to $13M at ~12.4%, saving $1.3M interest
New $13M Eclipse term loan at SOFR+7% (~12.4%), replacing $15M Avenue loan at ~15.9%.
Aytu BioPharma Q3 fiscal 2024 positive adjusted EBITDA $0.4M; ADHD revenue up 49% YoY
Q3 net loss $2.9M ($0.52/sh) vs $7.2M loss prior year; positive adjusted EBITDA $0.4M.
Aytu BioPharma reports Q2 fiscal 2024 operating income of $2.4M, first positive; ADHD revenue up 49%
Consolidated net revenue $22.9M, down 13% YoY due to planned wind-down of Consumer Health Segment.
Aytu BioPharma signs 5-year manufacturing contract with Halo for two ADHD products
Entered Commercial Manufacturing Services Agreement with Halo Pharmaceutical for Adzenys XR ODT and Cotempla XR ODT.
Aytu Q1 FY2024: Adjusted EBITDA $2.2M (+32% YoY), ADHD revenue up 31%
Net revenue $22.1M (down 20% YoY) due to Consumer Health wind-down; Rx segment $17.8M.
Aytu BioPharma receives FDA approval for Cotempla XR-ODT site transfer, expects margin boost in 2024
FDA approved Cotempla XR-ODT Prior Approval Supplement (PAS) for manufacturing transfer to contract manufacturer.
Aytu BioPharma COO resigns; company winding down manufacturing, suspending R&D
COO Christopher Brooke resigned effective Oct 13, 2023, to join a development-stage biotech.
Aytu Q4 record revenue $30.7M, positive Adj. EBITDA $7.7M, prescriptions up 32%
Q4 net revenue $30.7M (+12% YoY); Rx segment $23.3M (+24%); total prescriptions 155,562 (+32%).
Aytu BioPharma approves $118K CEO bonus and $83K CFO bonus for 2023
CEO Joshua R. Disbrow awarded $118,000 bonus (33% of target).
Exclusive collaboration, distribution and supply agreement for Adzenys XR-ODT and Cotempla XR-ODT in Israel and Palestinian Authority.
Aytu submits Cotempla XR-ODT site transfer PAS to FDA; expects 15% margin improvement on ADHD brands
Submitted Cotempla XR-ODT Prior Approval Supplement to FDA; expects six-month review with approval by late 2023/early 2024.
Gross proceeds of ~$4M from 1.74M shares and pre-funded warrants at $1.84/unit; offering expected to close June 13, 2023.
AYTU Biopharma stockholders approve 2023 equity incentive plan and elect all director nominees
All five director nominees elected; For votes ranged 673,707–685,411, Withheld 304,133–315,837.
Aytu BioPharma Q3 revenue $22.7M (-6% YoY); net loss narrows to $7.2M
Total net revenue $22.7M, down 6% from $24.2M; net loss ($7.2M) vs ($53.3M) last year.
Subleases 22,909 sq ft (~30%) of Grand Prairie, TX facility to AMTMS; base rent $20,045/mo through Dec 2023, then $21,000/mo until expansion.
Aytu BioPharma gets FDA approval for Adzenys site transfer; 15% margin improvement expected
FDA approved Prior Approval Supplement to transfer Adzenys XR-ODT manufacturing to contract manufacturer in 2023.
Preliminary discussions underway for potential strategic transactions and financing options.
Aytu BioPharma increases Eclipse revolving credit facility by $2M to $14.5M
Eclipse Amendment No. 4 increased revolving loan commitment by $2M, total facility now $14.5M.
Aytu BioPharma restates Q1 FY2023 financials; warrant misclassification adds $5.6M liabilities
Audit committee concludes Sep 30, 2022 financials should be restated due to warrant misclassification as equity instead of liabilities.
Net revenue $26.3M, up 14% YoY; Rx segment $18.0M (+23%) driven by 95% growth in pediatric products.
Aytu BioPharma enters amended employment agreements with CEO Josh Disbrow and CFO Mark Oki
CEO Disbrow’s agreement amended to one-year terms with auto-renewal; change of control acceleration requires termination within 12 months.
Delayed filing of Form 10-Q for quarter ended Dec 31, 2022 pending management review of warrant accounting from prior financings.
Aytu BioPharma regains Nasdaq minimum bid price compliance
Received Nasdaq notification on Jan 23, 2023 confirming bid price compliance.
Aytu BioPharma enacts 1-for-20 reverse stock split to regain Nasdaq $1.00 bid compliance
1-for-20 reverse split reduces outstanding shares from ~68.8M to ~3.4M.
Settlement cancels 387,804 of 1,551,216 shares (25%) from 2021 option grants to directors and officers.
Director Gary Cantrell to retire from Aytu BioPharma board effective Dec. 31, 2022
Gary Cantrell notified Aytu BioPharma of his intention to retire from the Board, effective December 31, 2022.
Aytu BioPharma dismisses Plante & Moran, appoints Grant Thornton as auditor
Dismissed Plante & Moran on Dec 12, 2022; reports had no adverse opinions but FY2022 included going concern explanatory paragraph.
On November 11, 2024, the board of directors of the Company (the " Board ") appointed Ryan Selhorn as Chief Financial Officer, Corporate Secretary and Treasurer of the Company.
On November 11, 2024, Mark K. Oki was terminated as Chief Financial Officer of the Company.
On October 3, 2023, Christopher Brooke resigned as Chief Operating Officer of Aytu BioPharma, Inc. (the “Company”), effective October 13, 2023, to pursue another opportunity at a development-stage biotechnology company.
Pursuant to the terms of the Purchase Agreement, effective as of the closing of the Offering, the size of the Board will be increased from four (4) to five (5), and Abhinav Jain shall be appointed to the Board.
On December 22, 2022, Gary Cantrell, a member of the Board of Directors of Aytu BioPharma, Inc. (the “Company”), notified the Company of his intention to retire from the Company's Board of Directors, effective December 31, 2022.
Effective November 14, 2022, Aytu BioPharma, Inc. (the “Company”) appointed Christopher Brooke as Chief Operating Officer
On June 24 2022, the Board of Directors of Aytu BioPharma, Inc. (the “Company”) appointed Vivian Liu to the Board of Directors, effective July 1, 2022.
On January 4, 2022, Aytu issued a press release announcing the appointment of Mr. Oki as Chief Financial Officer of the Company effective January 17, 2022.
On December 8, 2021, Richard I. Eisenstadt resigned as Chief Financial Officer of Aytu BioPharma, Inc. (the “Company”), effective December 30, 2021, to pursue another opportunity at a development-stage pharmaceutical company.
On August 30, 2021, Steven J. Boyd resigned as a members of the board of directors of Aytu BioPharma, Inc. (the “Company”).
Max materiality 0.85 · Median 0.60 · Most common event other_material